% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Machado:138664,
      author       = {Machado, Venissa and Gilsbach, Ralf and Das, Richa and
                      Schober, Andreas and Bogatyreva, Lioudmila and Hauschke,
                      Dieter and Krieglstein, Kerstin and Unsicker, Klaus and
                      Spittau, Björn},
      title        = {{G}df-15 deficiency does not alter vulnerability of
                      nigrostriatal dopaminergic system in {MPTP}-intoxicated
                      mice.},
      journal      = {Cell $\&$ tissue research},
      volume       = {365},
      number       = {2},
      issn         = {0302-766X},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DZNE-2020-04986},
      pages        = {209-223},
      year         = {2016},
      abstract     = {Growth/differentiation factor-15 (Gdf-15) is a member of
                      the transforming growth factor-β (Tgf-β) superfamily and
                      has been shown to be a potent neurotrophic factor for
                      midbrain dopaminergic (DAergic) neurons both in vitro and in
                      vivo. Gdf-15 has also been shown to be involved in
                      inflammatory processes. The aim of this study was to
                      identify the role of endogenous Gdf-15 in the MPTP
                      (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model
                      of Parkinson's disease (PD) by comparing Gdf-15 (+/+) and
                      Gdf-15 (-/-) mice. At 4 days and 14 days post-MPTP
                      administration, both Gdf-15 (+/+) and Gdf-15 (-/-) mice
                      showed a similar decline in DAergic neuron numbers and in
                      striatal dopamine (DA) levels. This was followed by a
                      comparable restorative phase at 90 days and 120 days,
                      indicating that the absence of Gdf-15 does not affect the
                      susceptibility or the recovery capacity of the nigrostriatal
                      system after MPTP administration. The MPTP-induced
                      microglial and astrocytic response was not significantly
                      altered between the two genotypes. However, pro-inflammatory
                      and anti-inflammatory cytokine profiling revealed the
                      differential expression of markers in Gdf-15 (+/+) and
                      Gdf-15 (-/-) mice after MPTP administration. Thus, the MPTP
                      mouse model fails to uncover a major role of endogenous
                      Gdf-15 in the protection of MPTP-lesioned nigrostriatal
                      DAergic neurons, in contrast to its capacity to protect the
                      6-hydroxydopamine-intoxicated nigrostriatal system.},
      keywords     = {1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine:
                      administration $\&$ dosage / Animals / Biomarkers:
                      metabolism / Cell Proliferation / Cytokines: metabolism /
                      Dopaminergic Neurons: metabolism / Growth Differentiation
                      Factor 15: deficiency / Growth Differentiation Factor 15:
                      metabolism / Inflammation Mediators: metabolism / Mice /
                      Neostriatum: metabolism / Neostriatum: pathology /
                      Neuroglia: metabolism / RNA, Messenger: genetics / RNA,
                      Messenger: metabolism / Substantia Nigra: metabolism /
                      Substantia Nigra: pathology / Biomarkers (NLM Chemicals) /
                      Cytokines (NLM Chemicals) / Gdf15 protein, mouse (NLM
                      Chemicals) / Growth Differentiation Factor 15 (NLM
                      Chemicals) / Inflammation Mediators (NLM Chemicals) / RNA,
                      Messenger (NLM Chemicals) /
                      1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (NLM
                      Chemicals)},
      cin          = {Pre 2020 / AG Brömer 1 / Bonn common},
      ddc          = {610},
      cid          = {I:(DE-2719)999999 / I:(DE-2719)5000021 /
                      I:(DE-2719)6000011},
      pnm          = {341 - Molecular Signaling (POF3-341)},
      pid          = {G:(DE-HGF)POF3-341},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27115420},
      doi          = {10.1007/s00441-016-2406-x},
      url          = {https://pub.dzne.de/record/138664},
}